Latest Kaiser Health News Stories
A federal drug program blocks rural hospitals from getting discounts on rare-disease drugs, forcing staff to cut back on supplies of lifesaving medicines.
Not only are health prices hidden, industry players are contractually obligated to keep them secret. That’s why answering a simple question — how much does it cost to have a baby in Mountain View, Calif.? — became a journalistic quest.
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
Gobbling up doctors’ independent practices is lucrative for hospital systems — but not necessarily a good deal for the physicians or consumers, critics say. Northern California is a case in point.
This immunization may mark a shift among some vaccine makers to higher-priced, “niche” preventives that protect against very specific and sometimes rare illnesses.
Under a five-year agreement with the federal government, California is using Medicaid dollars to expand drug treatment, including more inpatient care and a broader range of medications.
The federal health law includes a provision that allows states to alter some of its rules if they can think of a better way to provide health care to their residents, but it’s not clear how far outside the box states can go.
Hospice care often prompts fear and misunderstanding, but the services provided can lead to less pain and trauma at the end of life.
Most acquisitions by hospitals of physician practices are too small to trigger antitrust attention, study says. But a buying spree of “onesies and twosies” doctor practices has driven competition down and prices up.
Fed up with high hospital costs and limited competition, Santa Barbara County sends willing employees out of town for better bargains. Local governments are slowly joining private employers in aggressively seeking out the best care for the lowest price.
The federal government plans to spend millions of dollars less this year on advertising and outreach efforts to support the health law’s open enrollment period, which starts Nov. 1.
Study suggests that many small tumors are sleepy, not deadly.
The USA’s first approved gene therapy — to be used to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment.
As lawmakers look for ways to stabilize the health law marketplaces, a number of ideas — such as expanding who can “buy in” to Medicare and Medicaid or pushing young adults off their parents’ plans into the marketplaces — might come into play.
A genetically altered cancer drug, based on CAR T-cell therapies, could be a big success with leukemia patients but at a staggering cost.
This is the first federal website designed to help families choose a hospice, but experts aren’t impressed.
When leaders in Washington discuss the future of American health care, women are not always in the room. Here, nine women share their personal stories, fears and hopes.
Growing numbers of physicians say they support a single-payer health care system, a 180-degree turn in opinion over a decade.
Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
Kaiser Health News gives readers a chance to respond, react and comment on our stories.